SLC6A1-related neurodevelopmental disorder is rare, and expertise, patients, research and resources are spread across many countries. European collaboration is therefore essential to accelerate research, prepare for clinical trials and improve access to expertise and future therapies.

 

A European alliance does not replace national organisations. It strengthens them. By aligning strategy while respecting national autonomy, SLC6A1 Europe, Research & Support Alliance (SERSA) ensures that progress in one country benefits families across all of Europe.

 

By uniting national patient organisations under one coordinated structure, SERSA strengthens Europe’s collective impact in four critical areas:

​

1. Research: Rare disease research depends on sufficient patient numbers and organised data. A pan-European SLC6A1 alliance enables larger, structured datasets that are essential for natural history studies, biomarker validation, and regulatory-grade evidence generation.

​

2. Clinical Trial Readiness Across Borders: Therapeutic development requires coordinated trial sites, consistent protocols, and aligned regulatory engagement. A European network reduces duplication and accelerates site activation across multiple countries.

​

3. Regulatory and Policy Influence: Engagement with European regulatory bodies, including the European Medicines Agency (EMA), is more effective when representing a unified European patient voice rather than isolated national initiatives.

​

4. Equity of Access: Access to diagnosis, expertise, and emerging therapies varies across Europe. A coordinated alliance works toward structured standards and shared best practices to reduce disparities between countries.